Trials / Completed
CompletedNCT00679224
An Observational Study For Ambrisentan
A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 800 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
Detailed description
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ambrisentan | ambrisentan |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2008-05-16
- Last updated
- 2017-03-23
Locations
112 sites across 15 countries: Australia, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Slovakia, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00679224. Inclusion in this directory is not an endorsement.